Marc Duey Biography and Net Worth

Director of Aprea Therapeutics

Marc Duey has served as a member of our Board of Directors since May 2022 and previously served on the Board of Directors of Atrin Pharmaceuticals Inc. at the time of its acquisition by Aprea. He brings over three decades of experience in the pharmaceutical and biotechnology industries. Mr. Duey is the Founder, President and CEO of ProMetrics Inc. Prior to founding ProMetrics, Mr. Duey was founder and President of DuWest Research, an international management consulting firm for diagnostic and biotechnology companies. He serves on the Board of Trustees of International House Philadelphia and is a member of the Leadership Council of the Wistar Institute. He is an active member of the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), the American Association of Pharmaceutical Science (AAPS), and the Licensing Executive Society (LES). Mr. Duey holds a B.S. and an M.S. degree in science from the University of Ottawa, and an M.B.A. from the Ivey Business School at Western University, London, Canada.

What is Marc Duey's net worth?: The estimated net worth of Marc Duey is at least $155.23 thousand as of December 10th, 2025. Duey owns 256,155 shares of Aprea Therapeutics stock worth more than $155,230 as of October 7th. This net worth approximation does not reflect any other assets that Duey may own. Learn More about Marc Duey's net worth.
How do I contact Marc Duey?: The corporate mailing address for Duey and other Aprea Therapeutics executives is 3805 Old Easton Road, Doylestown, PA, 18902. Aprea Therapeutics can also be reached via phone at (215) 948-4119 and via email at [email protected]. Learn More on Marc Duey's contact information.
Has Marc Duey been buying or selling shares of Aprea Therapeutics?: Marc Duey has not been actively trading shares of Aprea Therapeutics over the course of the past ninety days. Most recently, on Wednesday, December 10th, Marc Duey bought 21,459 shares of Aprea Therapeutics stock. The stock was acquired at an average cost of $1.17 per share, with a total value of $25,107.03. Following the completion of the transaction, the director now directly owns 256,155 shares of the company's stock, valued at $299,701.35. Learn More on Marc Duey's trading history.
Who are Aprea Therapeutics' active insiders?: Aprea Therapeutics' insider roster includes Lars Abrahmsen (SVP), Eyal Attar (SVP), Marc Duey (Director), Oren Gilad (CEO), John Hamill (CFO), and Gregory Korbel (SVP). Learn More on Aprea Therapeutics' active insiders.
Are insiders buying or selling shares of Aprea Therapeutics?: In the last year, Aprea Therapeutics insiders bought shares 2 times. They purchased a total of 26,459 shares worth more than $30,957.03. The most recent insider tranaction occured on December, 10th when Director Marc Duey bought 21,459 shares worth more than $25,107.03. Insiders at Aprea Therapeutics own 10.5% of the company. Learn More about insider trades at Aprea Therapeutics.
Information on this page was last updated on 12/10/2025.

Marc Duey Insider Trading History at Aprea Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/10/2025	Buy	21,459	$1.17	$25,107.03	256,155
10/18/2024	Sell	6,462	$4.58	$29,595.96	233,651
10/16/2024	Buy	30,000	$4.39	$131,700.00	240,113
10/14/2024	Buy	190	$2.58	$490.20	210,113

Marc Duey Buying and Selling Activity at Aprea Therapeutics

Aprea Therapeutics Company Overview

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Today's Range

Now: $0.61

$0.58

$0.64

50 Day Range

MA: $0.73

$0.60

$0.98

2 Week Range

Now: $0.61

$0.55

$1.69

Volume

248,511 shs

Average Volume

898,562 shs

Market Capitalization

$7.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66